Eliciting Preferences to Inform Patient-Centred Policies: the Case of Psoriasis

Patient Preferences for Biologic Agents in Rheumatoid Arthritis: A Discrete-Choice Experiment

(2013) Federico Augustovski et al.   VALUE IN HEALTH

Constructing Experimental Designs for Discrete-Choice Experiments: Report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force

(2013) F. Reed Johnson et al.   VALUE IN HEALTH

Comparative Effectiveness of Commonly Used Systemic Treatments or Phototherapy for Moderate to Severe Plaque Psoriasis in the Clinical Practice Setting

(2012) Joy Wan   ARCHIVES OF DERMATOLOGY

Outcomes associated with matching patients' treatment preferences to physicians' recommendations: study methodology

(2012) Nasir Umar et al.   BMC HEALTH SERVICES RESEARCH

The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial)

(2012) Robert Strohal et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Patient preferences for psoriasis treatments: impact of treatment experience

(2012) M.-L. Schaarschmidt et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Patient Preferences for Psoriasis Treatments

(2011) Marthe-Lisa Schaarschmidt   ARCHIVES OF DERMATOLOGY

Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis

(2011) B.E. Strober et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1)

(2011) J. Barker et al.   BRITISH JOURNAL OF DERMATOLOGY

The value to patients of reducing lesion severity in plaque psoriasis

(2011) A. Brett Hauber et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Comorbidities significantly impact patients’ preferences for psoriasis treatments

(2011) Astrid Schmieder et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Conjoint Analysis Applications in Health—a Checklist: A Report of the ISPOR Good Research Practices for Conjoint Analysis Task Force

(2011) John F.P. Bridges et al.   VALUE IN HEALTH

Discrete choice experiments in health economics: a review of the literature

(2010) Esther W. de Bekker-Grob et al.   HEALTH ECONOMICS

British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009

(2009) C.H. Smith et al.   BRITISH JOURNAL OF DERMATOLOGY

Willingness-to-pay and quality of life in patients with vitiligo

(2009) M.A. Radtke et al.   BRITISH JOURNAL OF DERMATOLOGY

Heterogeneity in preferences for smoking cessation

(2008) Robert W. Paterson et al.   HEALTH ECONOMICS

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET

Conducting Discrete Choice Experiments to Inform Healthcare Decision Making

(2008) Emily Lancsar et al.   PHARMACOECONOMICS

Preference heterogeneity and choice of cardiac rehabilitation program: Results from a discrete choice experiment

(2007) Trine Kjær et al.   HEALTH POLICY

Modelling heterogeneity in patients’ preferences for the attributes of a general practitioner appointment

(2007) Arne Risa Hole   JOURNAL OF HEALTH ECONOMICS